OVERVIEW
Human epididymis protein 4 (HE4) is a novel biomarker that has been cleared by the U.S. Food and Drug Administration (FDA) for monitoring patients with epithelial ovarian cancer. HE4 is proposed as a replacement for or a complement to cancer antigen 125 (CA-125) for monitoring disease progression and recurrence. HE4 has also been proposed as a test to evaluate women with ovarian masses and to screen for ovarian cancer in asymptomatic women.

MEDICAL CRITERIA
Not applicable

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
Medicare Advantage Plans
Measurement of Human epididymis protein 4 is not covered for all indications as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products
Measurement of Human epididymis protein 4 is not medically necessary for all indications as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND
Human epididymis protein 4 is a novel biomarker that has been cleared by the FDA for monitoring patients with epithelial ovarian cancer. HE4 is proposed as a replacement for or a complement to cancer antigen 125 (CA-125) for monitoring disease progression and recurrence. HE4 has also been proposed as a test to evaluate women with ovarian masses and to screen for ovarian cancer in asymptomatic women.

Ovarian cancer is the fifth most common cause of cancer mortality among U.S. women. According to Surveillance Epidemiology and End Results data, in 2020, an estimated 21,750 women will be diagnosed with ovarian cancer and 13,940 women will die of the disease. The stage at diagnosis is an important predictor of survival; however, most women are not diagnosed until the disease has spread. For the period 1999 to 2006, 62% of women with ovarian cancer were diagnosed when the disease had distant metastases (stage IV), and this was associated with a 5-year survival rate of 28.9%. In contrast, 14.8% of women diagnosed with localized cancer (stage I) had a 5-year survival rate of 92.5%. Epithelial ovarian tumors account for 85% to 90% of ovarian cancers.

The standard treatment for epithelial ovarian cancer is surgical staging and primary cytoreductive surgery followed by chemotherapy in most cases. There is a lack of consensus about an optimal approach to follow-up of patients with ovarian cancer after or during primary treatment. Patients undergo regular physical
examinations and may have imaging studies. In addition, managing patients with serial measurement of the biomarker cancer antigen 125 (CA 125) to detect early recurrence of disease is common. A rising CA 125 level has been found to correlate with disease recurrence and has been found to detect recurrent ovarian cancer earlier than clinical detection. However, a survival advantage of initiating treatment based on early detection with CA 125 has not been demonstrated to date. For example, a 2010 randomized controlled trial (RCT) with women having ovarian cancer that was in complete remission did not find a significant difference in overall survival when treatment for remission was initiated after CA 125 concentration exceeded twice the limit of normal compared with delaying treatment initiation until symptom onset.

Human epididymis protein 4 (HE4) is a protein that circulates in the serum and has been found to be overexpressed in epithelial ovarian cancer, lung adenocarcinoma, breast cancer, pancreatic cancer, endometrial cancer, and bladder cancer. HE4 is made up of two whey acidic proteins with a four disulfide core domain and has been proposed as a biomarker for monitoring patients with epithelial ovarian cancer. This also addresses use of the HE4 as a stand-alone test for evaluating women with ovarian masses who have not been diagnosed with ovarian cancer. Such patients undergo a diagnostic workup to determine whether the risk of malignancy is sufficiently high to warrant surgical removal. In patients for whom surgery is indicated, further evaluation may be warranted to determine if surgical referral to a specialist with expertise in ovarian cancer is warranted. The Risk of Ovarian Malignancy Algorithm (ROMA) combines HE4, CA 125, and menopausal status into a numeric score.

Regulatory Status
Multiple HE4 test kits have been cleared by the Food and Drug Administration through the 510(k) process. The FDA determined that this device was substantially equivalent to a CA 125 assay kit for use as an aid in monitoring disease progression or recurrence in patients with epithelial ovarian cancer. The FDA-approved indication states that serial testing for HE4 should be done in conjunction with other clinical methods used for monitoring ovarian cancer and that the HE4 test is not intended to assess the risk of disease outcomes.

For individuals who have ovarian cancer who receive measurement of serum biomarker human epididymis protein 4 (HE4), the evidence includes 4 nonrandomized prospective and retrospective studies comparing the diagnostic accuracy of HE4 and CA 125 for predicting disease progression and/or recurrence. The relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, other test performance measures, and change in disease status. Data submitted to the U.S. Food and Drug Administration for approval of commercial HE4 tests found that HE4 was not inferior to CA 125 for detecting ovarian cancer recurrence. Although a single prospective observational study found elevated levels of HE4, but not CA 125, at the time of cancer progression to be significantly associated with reduced overall survival, a direct comparison between biomarkers was not provided. Overall, the superiority of HE4 to CA 125 (alone or in combination), the key question in the evidence review, was not demonstrated in the available literature. In addition, there is no established cutoff in HE4 levels for monitoring disease progression, and cutoffs in studies varied. There is no direct evidence from prospective controlled studies on the impact of HE4 testing on health outcomes and no clear chain of evidence that changes in management based on HE4 would lead to improved health outcome. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have adnexal masses who receive measurement of serum biomarker HE4, the evidence includes diagnostic accuracy studies and meta-analyses. The relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and other test performance measures. Metaanalyses have generally found that HE4 and CA 125 have similar overall diagnostic accuracy (ie, sensitivity, specificity) and several found that HE4 has significantly higher specificity than CA 125 but not sensitivity. Two meta-analyses had mixed findings on whether the combination of HE4 and CA 125 is superior to CA 125 alone for the initial diagnosis of ovarian cancer. The number of studies evaluating the combined test is relatively low and publication bias in studies of HE4 has been identified. In addition, studies have not found that HE4
improves diagnostic accuracy beyond that of subjective assessment of transvaginal ultrasound. There is no
direct evidence from prospective controlled studies on the impact of HE4 testing on health outcomes and no
clear chain of evidence that changes in management based on HE4 would lead to improved health outcome.
The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are asymptomatic and not at high risk of ovarian cancer who receive screening with
serum biomarker HE4, the evidence includes several retrospective comparative studies and no prospective
studies comparing health outcomes in asymptomatic women managed with and without HE4 screening. The
relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, and other test
performance measures. The retrospective studies found that HE4 levels increased over time in women
ultimately diagnosed with ovarian cancer. Prospective comparative studies are needed to definitively
determine whether HE4 is a useful screening tool. The evidence is insufficient to determine the effects of the
technology on health outcomes.

CODING
The following CPT code is not covered for Medicare Advantage Plans and not medically necessary for
Commercial products:
86305 Human epididymis protein 4 (HE4)

RELATED POLICIES
CA-125
Multimarker Serum Testing Related to Ovarian Cancer

PUBLISHED
Provider Update, March 2021
Provider Update, March 2020
Provider Update, April 2019
Provider Update, Nov. /Dec. 2018
Provider Update, October 2017
Provider Update, January 2017
Provider Update, January 2016
Provider Update, December 2014

REFERENCES
1. Surveillance Epidemiology and End Results Program (SEER). SEER Stat Fact: Ovarian Cancer. n.d.;
2. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma:
6:vi24-32. PMID 24078660
4. Food and Drug Administration, 510(k) substantial equivalence determination decision summary:
5. Food and Drug Administration. 510(k) substantial equivalence determination decision summary:
outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. Feb
2013;128(2):245-251. PMID 23178313
This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.